Lexaria Bioscience Corp. (LEXX) stock
LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
$4.28+0.10 (+2.39%)
Close on Nov 18, 2026Market cap $106.09MP/E –Yield –
Lexaria Bioscience revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Lexaria Bioscience's revenue for the twelve months ending May 31, 2026 was $194.00K, down 68.5% year over year. For fiscal 2025 it was $705.92K, up 52.0% from the year before. Over ten years it grew 47.3% a year on average. The highest annual figure on record is $722.74K in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $705.92K | +52.0% |
| FY2024 | Aug 31, 2024 | $464.28K | +105.2% |
| FY2023 | Aug 31, 2023 | $226.21K | -11.4% |
| FY2022 | Aug 31, 2022 | $255.40K | -64.7% |
| FY2021 | Aug 31, 2021 | $722.74K | +129.6% |
| FY2020 | Aug 31, 2020 | $314.79K | +41.4% |
| FY2019 | Aug 31, 2019 | $222.61K | -48.6% |
| FY2018 | Aug 31, 2018 | $433.29K | +580.9% |
| FY2017 | Aug 31, 2017 | $63.64K | +56.3% |
| FY2016 | Aug 31, 2016 | $40.72K | +177.0% |
| FY2015 | Aug 31, 2015 | $14.70K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | May 31, 2026 | $0 | -100.0% |
| Q2 FY2026CQ1 2026 | Feb 28, 2026 | $20.00K | -88.5% |
| Q1 FY2026CQ4 2025 | Nov 30, 2025 | $0 | -100.0% |
| Q4 FY2025CQ3 2025 | Aug 31, 2025 | $174.00K | +107.1% |
| Q3 FY2025CQ2 2025 | May 31, 2025 | $174.00K | +107.1% |
| Q2 FY2025CQ1 2025 | Feb 28, 2025 | $174.00K | +20.0% |
| Q1 FY2025CQ4 2024 | Nov 30, 2024 | $183.92K | +21.6% |
| Q4 FY2024CQ3 2024 | Aug 31, 2024 | $84.00K | +173.3% |
| Q3 FY2024CQ2 2024 | May 31, 2024 | $84.00K | +8.1% |
| Q2 FY2024CQ1 2024 | Feb 29, 2024 | $145.00K | +624.1% |
| Q1 FY2024CQ4 2023 | Nov 30, 2023 | $151.28K | +54.8% |
| Q4 FY2023CQ3 2023 | Aug 31, 2023 | $30.74K | -72.3% |
| Q3 FY2023CQ2 2023 | May 31, 2023 | $77.71K | -22.1% |
| Q2 FY2023CQ1 2023 | Feb 28, 2023 | $20.03K | -34.7% |
| Q1 FY2023CQ4 2022 | Nov 30, 2022 | $97.74K | +604.1% |
| Q4 FY2022CQ3 2022 | Aug 31, 2022 | $111.15K | +258.3% |
| Q3 FY2022CQ2 2022 | May 31, 2022 | $99.72K | -51.1% |
| Q2 FY2022CQ1 2022 | Feb 28, 2022 | $30.65K | -84.0% |
| Q1 FY2022CQ4 2021 | Nov 30, 2021 | $13.88K | -95.3% |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | $31.02K | -51.5% |
| Q3 FY2021CQ2 2021 | May 31, 2021 | $204.06K | +460.2% |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | $192.01K | +411.3% |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | $295.66K | +2761.6% |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | $63.99K | -48.9% |
| Q3 FY2020CQ2 2020 | May 31, 2020 | $36.42K | -39.2% |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | $37.55K | +144.6% |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | $10.33K | -53.5% |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | $125.12K | +29.9% |
| Q3 FY2019CQ2 2019 | May 31, 2019 | $59.93K | -57.3% |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | $15.35K | -91.1% |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | $22.21K | -9.8% |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | $96.35K | +667.2% |
| Q3 FY2018CQ2 2018 | May 31, 2018 | $140.34K | +379.7% |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | $171.96K | +1264.5% |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | $24.64K | +167.0% |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | $12.56K | +46.7% |
| Q3 FY2017CQ2 2017 | May 31, 2017 | $29.25K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | $12.60K | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | $9.23K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | $8.56K | – |
See a number that looks wrong?